Independent fund research. Built on SEC filings.

How we research funds

Mutual fund · Small-Cap · Transamerica

Transamerica Small Cap Growth A (ASGTX)

Ticker ASGTX · Since 2012-08-31 · · Holdings as of Jul 31, 2026

Expense ratio
1.4%$140/yr per $10k
5-yr return
−1.3%annualized
1-yr return
−8.6%as of Dec 2025
Net assets
$80.8Mall share classes
Holdings
58

Bottom line

Is ASGTX a good fund? The bottom line

ASGTX is a share class of Transamerica Small Cap Growth, a managed small-cap mutual fund from Transamerica.

Its expense ratio is 1.4% — about $140 a year on every $10,000 invested, more expensive than 82% of small-cap funds we track.

It returned −8.6% over one year, −1.3% a year over five years, +7.3% a year over ten (as of Dec 31, 2025, per its prospectus).

With $80.8 million in net assets and 58 holdings, its largest position is Ligand Pharmaceuticals Inc (4.5%) and the top 10 make up 29.8% of the portfolio.

This share class carries a front-end sales charge of up to 5.5%; a no-load class or ETF alternative can avoid it.

What to watch

  • Expensive for its category (1.4%)
  • 5-year return in the bottom quarter of its category
  • Front-end sales load up to 5.5%
  • 12b-1 marketing fee of 0.25% a year

Updated Nov 19, 2026

What ASGTX invests in

Seeks long-term capital appreciation.

Under normal circumstances, the fund invests at least 80% of its net assets (plus the amount of borrowing, if any, for investment purposes) in stocks of small capitalization companies. The funds sub-adviser, Ranger Investment Management, L.P. (the sub-adviser), primarily focuses on seeking to identify high quality, high-growth small capitalization companies. The sub-adviser considers small capitalization companies to be companies with market capitalizations which, at the initial time of purchase, are within the capitalization range of issuers represented within the Russell 2000 Growth Index 1 , a benchmark of the fund, which as of June 27, 2025, the most recent reconstitution date of the index, was between $119.4 million and $7.4 billion. The sub-advisers approach to security selection seeks quality growth companies by implementing a bottom-up, fundamental research driven security…

From the fund's prospectus (filed Feb 27, 2026).

ASGTX performance

Fund calendar-year total returns, 2016–2025 2016: +19.4%; 2017: +15.1%; 2018: −7.6%; 2019: +29.1%; 2020: +31.7%; 2021: +17.4%; 2022: −31.2%; 2023: +19.6%; 2024: +5.8%; 2025: −3.3% +19% 2016 +15% 2017 −8% 2018 +29% 2019 +32% 2020 +17% 2021 −31% 2022 +20% 2023 +6% 2024 −3% 2025
Fund gain (+) Fund loss (−)
Average annual total returns
1 yr5 yr10 yr
ASGTX−8.6%−1.3%+7.3%
Small-Cap median+7.6%+7.0%+9.2%

Source: Fund prospectus, as of Dec 31, 2025

Full ASGTX performance history →

What ASGTX costs

On a $10,000 investment, ASGTX's 1.4% expense ratio costs about $140 a year. The prospectus estimates $2,272 in total costs over 10 years (assuming 5% annual returns). The median small-cap fund charges 0.99%.

See the full ASGTX fee table →

ASGTX top 10 holdings

#Holding% of fund
1Ligand Pharmaceuticals Inc4.49%
2SharkNinja Inc3.33%
3UL Solutions Inc3.27%
4Oceaneering International Inc3.11%
5Chime Financial Inc2.84%
6HealthEquity Inc2.74%
7PDF Solutions Inc2.66%
8Triumph Financial Inc2.46%
9Casella Waste Systems Inc2.45%
10Excelerate Energy Inc2.44%

Source: SEC Form N-PORT, period ended Jul 31, 2026

The top 10 make up 29.8% of the fund. See all top 25 holdings and asset mix →

Alternatives to ASGTX

More funds like ASGTX →

ASGTX FAQ

What is the expense ratio of ASGTX?
ASGTX's expense ratio is 1.4%, which works out to about $140 a year for every $10,000 invested. The prospectus estimates total costs of $2,272 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is ASGTX a good investment?
It depends on your goals, but the data points to: expensive for its category (1.4%); 5-year return in the bottom quarter of its category; front-end sales load up to 5.5%; 12b-1 marketing fee of 0.25% a year. This is general information, not personalized advice.
What does ASGTX hold?
ASGTX's largest holdings are Ligand Pharmaceuticals Inc (4.5%), SharkNinja Inc (3.3%), UL Solutions Inc (3.3%), Oceaneering International Inc (3.1%), Chime Financial Inc (2.8%). It holds 58 positions in total as of Jul 31, 2026 (SEC Form N-PORT).
What is ASGTX's 5-year return?
ASGTX returned −1.3% a year over the five years ending Dec 31, 2025, and +7.3% a year over ten years. Past performance does not guarantee future results.
Does ASGTX have a sales load?
Yes. ASGTX has a maximum front-end sales charge of 5.5%.
Who manages ASGTX?
ASGTX is offered by Transamerica through Transamerica Funds.